So, you want to know if MariMed, one of the cannabis industry’s better-known names, is going out of business. Maybe you’ve seen rumors online or heard someone mention bankruptcy. Or maybe you’re an investor wondering if your shares are safe, or just a curious observer watching the wild swings in the weed business. Let’s clear things up with a real update, straight from the numbers, filings, and a few practical indicators no drama and no marketing-speak.
MariMed’s Current Status: Still Standing, Not Sinking
As of late 2025, MariMed is not going out of business. The company is still operating its dispensaries, launching products, paying its bills, and filing updates with regulators. That’s the short answer, but there’s more behind it.
The cannabis industry has definitely been through a rough patch lately. Overexpansion, heavy taxes, price wars, and regulatory confusion have hit plenty of players hard. Some, like 4Front Ventures and smaller outfits, haven’t made it. But MariMed? They’re still running at full speed.
Financial Performance: Holding the Line in a Tough Market
Let’s start with the money, since that’s what usually shuts the doors at a business.
In the second quarter of 2025, MariMed’s earnings per share were dead even break-even. That surprised quite a few Wall Street watchers, since they’d expected the company to lose money in these conditions. Revenue was a bit lower year-over-year. That’s pretty common in cannabis right now, with prices squeezed and consumers tightening belts.
But they’re keeping cash flow positive. And their EBITDA margin if you’re not into finance-speak, that means how much core profit they’re making before taxes and debt was about 12%. That’s a decent sign of operational discipline, especially since a bunch of their peers are seeing negative cash flow or outright losses.
Back in November 2023, MariMed refinanced $58.7 million in debt. Sounds dull, but imagine reorganizing your credit card loans for a better rate, freeing up more monthly cash. They paid off higher-interest obligations and now have more breathing room. They haven’t defaulted on those payments or raised any red flags with lenders since.
Still, investors have noticed the slower growth and market stress. MariMed’s share price slipped about 9% since the start of 2025. Not great, but not a disaster for a cannabis stock these days. Importantly, there’s no sign of missing payments, rapid asset sales, or emergency financings things you’d expect to see if a company was circling the drain.
Operational Moves and Leadership’s Approach
If you walk into a MariMed dispensary, you’re not going to see “Closing Sale” signs. They’re still launching new products Betty’s Eddies, for example, got a refresh this year with new flavors. MariMed is putting money into markets with potential, too, like Maryland and Missouri. That’s not what a business on the brink would do.
Jon Levine, MariMed’s CEO, isn’t promising wild expansion or magical turnarounds. He’s been direct about the challenges: high taxes, pricing pressure, regulatory slowdowns. The company is choosing “disciplined” expansion, picking their spots, rather than chasing every new state.
This attitude shows up in their filings. The latest SEC reports show operating leases in place through at least 2026, with options to extend. They’re still signing rental agreements and reporting regular business activities. In December 2025, the company even put out a short statement backing cannabis’ reclassification to Schedule III a regulatory shift that could free up tax advantages and banking access in the future.
Nothing in these public records hints at shutdowns or planned bankruptcy.
No Bankruptcy And How That’s Different from Others
Here’s where the numbers get technical for a second, but it’s worth explaining.
A third-party financial risk firm gave MariMed a “solvency score” of 25 out of 100 for 2025. That’s not a great score think of it like getting a “C-” on a financial health report. The specific bankruptcy probability? About 12.2%. Higher than a grocery chain or a boring old utility, but nowhere near what you’d see for a company about to file for Chapter 11. In fact, some of MariMed’s rivals have been much riskier, with multiple debt defaults and insolvency proceedings.
People sometimes misunderstand past headlines. MariMed was linked to Ermont Inc. but here’s the truth: MariMed bought assets from Ermont when Ermont’s business was in receivership. MariMed itself hasn’t filed for bankruptcy. In fact, SEC filings always include generic “what if we go bankrupt” scenarios, but that’s just standard for public companies facing ANY risk. There’s no active process or even signals pointing to an imminent bankruptcy.
What Would Trouble Look Like? Here’s What to Watch
If you’re the super-cautious type, there are always potential warning signs you can keep an eye on. For companies, the big indicators of trouble are missed loan payments, skipped lease checks, surprise resignations of top leadership, or delays in filing financial reports. None of those are happening at MariMed as 2025 wraps up.
Revenue is down a little. The stock isn’t lighting up Wall Street’s screens. But these are issues across nearly every company in the cannabis sector right now. MariMed seems to be adapting: in markets that aren’t performing, they’re trimming costs and reworking their approach, rather than doubling down or making risky bets.
It’s worth noting that, while their 12.2% bankruptcy probability isn’t zero, it’s described by outside advisers as “moderate but notable.” For reference, many cannabis companies are carrying far higher bankruptcy odds—some with loaded-up debt and no sign of turning things around.
If things were headed south for MariMed fast, you’d likely see emergency cost cuts, sudden executive shake-ups, or notices to lenders and vendors. So far, those just aren’t there.
The Bigger Picture: Context Matters
The cannabis industry is not easy territory these days, even for established brands. Ongoing federal prohibition means trouble with banking, higher operating costs, and a persistent stigma with some investors. Then, there are state-level taxes and intense pricing competition that cut into everyone’s margins.
That’s led to frequent shakeouts—companies with thin margins and heavy debt have been hit hardest. MariMed has stayed away from big, risky splurges. It held onto positive cash generation, watched its debt, and avoided too much real estate it couldn’t use.
In December 2025, MariMed actually welcomed the federal government’s hint at lighter cannabis restrictions. If reforms go through next year, that could open up access to loans and remove some taxes that suffocate profits. Still, it’s not something they’re banking the whole business on.
For more stories on steady operators and businesses weathering tough times, check out profiles at United Business Magazine—they cover everything from retailers to restaurants with this boots-on-the-ground approach.
So, Is MariMed Going Out of Business?
The numbers, statements, and even the market gossip all point to the same rough answer: no, MariMed is not on its way out as 2025 ends. The company’s keeping up with its bills, not signaling layoffs or shutdowns, and is still investing in new products and key states. Sure, there’s risk with every cannabis operator right now—but they aren’t showing the classic symptoms of a business in crisis.
Does this mean you should ignore them? Probably not. Anyone with skin in the game—or just a casual interest—should keep watching for updates to revenue, leadership moves, or any big changes in the legal landscape. Sector-wide challenges are real, and some companies won’t make it. So far, though, MariMed looks more like a survivor—steady, adapting, not chasing every shiny object.
As always, this isn’t financial advice, and the story could change with new regulations or shifts in the market. But for now, MariMed continues on, not going out of business, and handling the cannabis industry’s bumps a little better than some of its peers. That’s how it stands as 2025 comes to a close.
